About odevixibat
Ileal bile acid transporter inhibitor
Used for
- Treats itching caused by progressive familial intrahepatic cholestasis (PFIC) in eligible children.
- Treats itching caused by Alagille syndrome in eligible children.
Usual adult dose
Not established for adults; treatment is primarily for children.
Usual dose in children
PFIC: usually 40 micrograms/kg once daily; may increase to 120 micrograms/kg. Alagille syndrome: usually 120 micrograms/kg once daily.
Common side effects
- Diarrhea or loose stools
- Abdominal pain
- Liver-test abnormalities
- Vitamin deficiencies, including vitamins A, D, E, and K
Important warnings
- Monitor liver tests and fat-soluble vitamin levels.
- Persistent diarrhea may require treatment interruption or dose adjustment.
- Avoid in complete biliary obstruction.
- May affect absorption of other medicines; separate doses when advised.
Pregnancy
Human pregnancy data are limited; use only when clearly needed and after weighing potential risks.
Breastfeeding
It is unknown whether odevixibat enters breast milk; consider potential infant exposure and treatment benefits.
Interactions
- Bile acid-binding resins may reduce absorption; separate administration by at least four hours.
- Caution with medicines whose absorption may be affected by reduced bile acids.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.